Artelo Biosciences, Inc. (ARTL) stock
Close on Nov 13, 2026Market cap $1.94MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $1.94M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.31
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$11.32M
- EPS, diluted
- -$12.52
- Book value per share
- $11.25
- Diluted shares
- 1M
Trading
- Previous close
- $2.10
- Open
- $2.17
- Day's range
- $2.05 – $2.25
- Volume
- 14,154
- Average volume (20 days)
- 40,012
- Beta (5 years)
- 0.21
- 52-week range
- $1.91 – $179.19
- RSI (14 days)
- 34.8
- Volatility (1 year)
- 278.0%
- Relative volume
- 0.04×
- WACC
- 7.6%
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | ARTL | S&P 500 | Difference | ARTL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -30.5% | -3.0% | −27.5 pts | ||
| 3 months | -69.7% | -2.8% | −66.9 pts | ||
| Year to date | -93.7% | +11.5% | −105.2 pts | ||
| 1 year | -95.7% | +13.5% | −109.2 pts | ||
| 3 years | -99.0% | +77.7% | −176.7 pts | -78.4% | +21.1% |
| 5 years | -99.9% | +72.6% | −172.5 pts | -75.1% | +11.5% |
Eleven years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases Artelo Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- Update
- Update
- Update
- Results
About Artelo Biosciences
Pharmaceutical Preparations
Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics that target lipid-signaling modulation pathways, including the endocannabinoid system. The company's pipeline includes ART27.13, a synthetic dual cannabinoid receptor agonist in clinical trials for cancer-related anorexia; ART26.12, an inhibitor of fatty acid binding protein 5 being evaluated for chemotherapy-induced peripheral neuropathy, cancer, and pain; and ART12.11, a proprietary cannabidiol cocrystal composition for anxiety disorders and depression. Because its drug candidates remain in clinical and preclinical stages, the company currently has no commercial sales, but aims to make prescription treatments available to patients following regulatory authorizations.
Company profile, executives and historyArtelo Biosciences stock: common questions
What is Artelo Biosciences's stock price?
ARTL closed at $2.07 on Nov 13, 2026, down 1.43% on the day. Over the past 52 weeks it traded between $1.91 and $179.19.
What is Artelo Biosciences's market cap?
Artelo Biosciences was worth $1.94M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is ARTL's P/E ratio?
Artelo Biosciences lost money over fiscal 2025 (diluted EPS -$12.52), so it has no meaningful P/E ratio.
Does Artelo Biosciences pay a dividend?
No. Artelo Biosciences has not paid a cash dividend over the last twelve months.
How has ARTL stock performed over the past year?
Including dividends, ARTL returned -95.7% over the past year, against +13.5% for the S&P 500.
How many ARTL shares are sold short?
0M shares were sold short at the latest FINRA report, 5.01% of the float, or 1.0 days of average trading volume.
Who are Artelo Biosciences's competitors?
Companies most similar to Artelo Biosciences by business, industry and size include CRBP, PBM, SKYE, AARD, NAMS.
See a number that looks wrong?